Redwood City, California-based Exo intends to integrate Medo’s proprietary Sweep AI technology into its ultrasound platform to make the imaging modality more accessible to a wider range of caregivers.
No financial terms for the acquisition were disclosed.
According to a news release, Canada-based Medo’s ultrasound AI technology radically lowers the expertise required to diagnose common and critical conditions through automated image acquisition and interpretation, giving non-experts the ability to conduct high-quality exams quickly and accurately.
The company brings with it two FDA-cleared AI algorithms, as well as more in development, plus access to an extensive library of millions of ultrasound images and longitudinal health data to speed up point-of-care ultrasound adoption across the healt…